Table 1.
Bacterial inhibitory concentration and relative bacterial inhibitory concentration values from activity measurements of GxxxG and GxxxG-like peptide variants of Pls-α and Pls-β together with the wild type complementary peptide.
| Peptide combinationb | Bacterial inhibitory concentration (nM) | Relative bacterial inhibitory concentration valuesa | ||
|---|---|---|---|---|
| Lac. lactis IL1403 | Lab. sakei NCFB 2714 | Lac. lactis IL1403 | Lab. sakei NCFB 2714 | |
| α + β | 0.6 ± 0.1 | 0.17 ± 0.04 | 1 | 1 |
| α(G9A) + β | 11.4 ± 0.9 | 3.7 ± 1.0 | 20 | 20 |
| α(G9L) + β | >25 | >25 | >40 | >150 |
| α(G13A) + β | 1.0 ± 0.1 | 0.36 ± 0.05 | 2 | 2 |
| α(G13L) + β | >25 | >25 | >40 | >150 |
| α(A15G) + β | 6.1 ± 1.5 | 1.25 ± 0.75 | 10 | 7 |
| α(A15L) + β | 0.7 ± 0.1 | 0.25 ± 0.04 | 1 | 1 |
| α(G19A) + β | 0.8 ± 0.2 | 0.22 ± 0.04 | 1 | 1 |
| α(G19L) + β | 4.3 ± 0.6 | 0.33 ± 0.02 | 7 | 2 |
| β(S6G) + α | 0.8 ± 0.1 | 0.23 ± 0.06 | 1 | 1 |
| β(S6A) + α | 0.6 ± 0.1 | 0.15 ± 0.05 | 1 | 1 |
| β(S6L) + α | 1.2 ± 0.1 | 0.29 ± 0.08 | 2 | 2 |
| β(A10G) + α | 1.7 ± 0.4 | 0.41 ± 0.12 | 2 | 2 |
| β(A10L) + α | 0.7 ± 0.1 | 0.26 ± 0.06 | 1 | 1 |
| β(A14G) + α | 3.1 ± 0.4 | 0.59 ± 0.09 | 5 | 3 |
| β(A14L) + α | 1.4 ± 0.1 | 0.36 ± 0.06 | 2 | 2 |
| β(S17G) + α | 5.4 ± 0.3 | 1.1 ± 0.35 | 9 | 6 |
| β(S17A) + α | 2.4 ± 0.2 | 0.51 ± 0.19 | 4 | 3 |
| β(S17L) + α | 10 ± 1 | 1.3 ± 0.9 | 17 | 8 |
| β(G21A) + α | 4.1 ± 0.3 | 1.0 ± 0.47 | 7 | 6 |
| β(G21L) + α | >25 | >25 | >40 | >150 |
aThe relative bacterial inhibitory concentration is defined as a fold increase or decrease in activity compared to the wild type combination.
bThe peptides were added in equimolar amounts. α and β are Pls-α and Pls-β, respectively. Single amino acid substitutions are indicated in parentheses.